# Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

> **NCT00813449** · PHASE2 · UNKNOWN · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 140 (estimated)

## Conditions studied

- Advanced Melanoma
- Untreated Patients

## Interventions

- **DRUG:** dacarbazine plus Endostar (Experimental group)
- **DRUG:** dacarbazine plus placebo (control group)

## Key facts

- **NCT ID:** NCT00813449
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2009-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813449, "Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00813449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*